Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Schlomm

Showing results (191-200 of 359) with videos related to

Pageof 36
Sort By:
The American Journal of Pathology|January 1, 2014
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletionMaria C Tsourlakis, Philipp Weigand, Katharina Grupp, et al.
Scientific Reports|August 10, 2022
Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsyKira Kornienko, Miriam Reuter, Andreas Maxeiner, et al.
Clinical Epigenetics|October 24, 2019
Random forest-based modelling to detect biomarkers for prostate cancer progressionReka Toth, Heiko Schiffmann, Claudia Hube-Magg, et al.
Journal of Clinical Medicine|December 10, 2021
Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients ≥75 YearsIlias Zompolas, Robert Peters, Lutz Liefeldt, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Human Pathology|February 22, 2015
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancersChristoph Burdelski, Ysé Barreau, Ronald Simon, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Clinical Chemistry|October 12, 2019
Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate CancerSimon A Joosse, Burkhard Beyer, Christin Gasch, et al.
British Journal of Cancer|September 9, 2020
EGFR as a stable marker of prostate cancer dissemination to bonesPaulina Nastały, Sara Stoupiec, Marta Popęda, et al.
Pageof 36

Showing results (191-200 of 359) with videos related to

Sort By:
Pageof 36
The American Journal of Pathology|January 1, 2014
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletionMaria C Tsourlakis, Philipp Weigand, Katharina Grupp, et al.
Scientific Reports|August 10, 2022
Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsyKira Kornienko, Miriam Reuter, Andreas Maxeiner, et al.
Clinical Epigenetics|October 24, 2019
Random forest-based modelling to detect biomarkers for prostate cancer progressionReka Toth, Heiko Schiffmann, Claudia Hube-Magg, et al.
Journal of Clinical Medicine|December 10, 2021
Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients ≥75 YearsIlias Zompolas, Robert Peters, Lutz Liefeldt, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Human Pathology|February 22, 2015
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancersChristoph Burdelski, Ysé Barreau, Ronald Simon, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Clinical Chemistry|October 12, 2019
Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate CancerSimon A Joosse, Burkhard Beyer, Christin Gasch, et al.
British Journal of Cancer|September 9, 2020
EGFR as a stable marker of prostate cancer dissemination to bonesPaulina Nastały, Sara Stoupiec, Marta Popęda, et al.
Pageof 36